Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-Current Assets: 2021-2025

Historic Non-Current Assets for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $33.9 million.

  • ARS Pharmaceuticals' Non-Current Assets rose 285.16% to $33.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.9 million, marking a year-over-year increase of 285.16%. This contributed to the annual value of $16.9 million for FY2024, which is 1053.08% up from last year.
  • ARS Pharmaceuticals' Non-Current Assets amounted to $33.9 million in Q3 2025, which was up 5.94% from $32.0 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Non-Current Assets' 5-year high stood at $51.1 million during Q1 2022, with a 5-year trough of $265,000 in Q3 2022.
  • Over the past 3 years, ARS Pharmaceuticals' median Non-Current Assets value was $4.1 million (recorded in 2023), while the average stood at $11.9 million.
  • Per our database at Business Quant, ARS Pharmaceuticals' Non-Current Assets crashed by 99.44% in 2022 and then spiked by 2,508.79% in 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Non-Current Assets (Quarterly) stood at $716,000 in 2021, then skyrocketed by 421.65% to $3.7 million in 2022, then crashed by 60.86% to $1.5 million in 2023, then soared by 1,053.08% to $16.9 million in 2024, then skyrocketed by 285.16% to $33.9 million in 2025.
  • Its Non-Current Assets was $33.9 million in Q3 2025, compared to $32.0 million in Q2 2025 and $23.5 million in Q1 2025.